SCHEMBL787533

SCHEMBL787533

CC(C)NC(=O)N1CCNCC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.69
SMN1; SMN2 Q16637 2/20 0.58
PKM P14618 1/20 0.58
CHRM5 P08912 1/20 0.55
CHRM3 P20309 1/20 0.55
CYP2C9 P11712 2/20 0.50
CYP2D6 P10635 2/20 0.47
CYP2C19 P33261 1/20 0.47
CA2 P00918 2/20 0.47
CHKA P35790 1/20 0.47
ALDH1A1 P00352 3/20 0.45
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA9 Q16790 1/20 0.43
POLB P06746 1/20 0.43
EPHX2 P34913 1/20 0.43
CYP3A4 P08684 2/20 0.42
CHRNB2 P17787 1/20 0.41
CHRNA3 P32297 1/20 0.41
CHRNA4 P43681 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL15709524 0.98 CYP1A2 (0.67) CYP1A2SMN1; SMN2PKMCHRM5CHRM3
SCHEMBL23464918 0.84
SCHEMBL8539756 0.84 CYP1A2 (0.51) CYP1A2SMN1; SMN2PKMCHRM5CHRM3
SCHEMBL3009879 0.82 SMN1; SMN2 (0.67) CYP1A2SMN1; SMN2PKMCYP2C9CYP2D6
SCHEMBL23331595 0.82 SMN1; SMN2 (0.67) CYP1A2SMN1; SMN2PKMCYP2C9CYP2D6
SCHEMBL19062102 0.82 CYP1A2 (0.50) CYP1A2SMN1; SMN2PKMCHRM5CHRM3
SCHEMBL8520670 0.81 CYP1A2 (0.49) CYP1A2SMN1; SMN2PKMCHRM5CHRM3
SCHEMBL3120355 0.80 SMN1; SMN2 (0.64) CYP1A2SMN1; SMN2PKMCYP2C9CYP2D6
SCHEMBL8521247 0.80 CYP1A2 (0.47) CYP1A2SMN1; SMN2PKMCHRM5CHRM3
SCHEMBL30404878 0.80 CYP1A2 (0.47) CYP1A2SMN1; SMN2PKMCHRM5CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3280707-B1 BICYCLIC QUINAZOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2023-12-20 EP claimed
CN-122079899-A Application of pharmaceutical composition in preparation of medicines for preventing or treating diseases related to Sirttail 7 protein 2026-05-26 CN disclosed
CN-116829542-A Benzothiazole and benzimidazole derivatives, pharmaceutically acceptable salts, preparation method thereof and pharmaceutical composition containing same as active ingredient 韩国化学研究院 2023-09-29 CN disclosed
CN-111212833-B Phenylpyridine derivatives and pharmaceutical compositions containing the same 株式会社大熊制药 2022-09-06 CN disclosed
EP-2900666-B1 AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C CANCER RESEARCH TECH LTD (GB) 2020-11-04 EP disclosed
EP-3322706-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS Array Biopharma, Inc. (US) 2018-05-23 EP disclosed
EP-2799435-B1 POLY (ADP-RIBOSE) POLYMERASE INHIBITOR CHENGDU DIAO PHARMACEUTICAL GROUP CO LTD (CN) 2018-03-28 EP disclosed
US-9914730-B2 Azaquinazoline inhibitors of Atypical protein Kinase C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-03-13 US disclosed
US-9896446-B2 Azaquinazoline inhibitors of atypical protein kinase C CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-02-20 US disclosed
US-9718841-B2 Bicyclic pyrazolone compounds and methods of use CALITOR SCIENCES, LLC (US) 2017-08-01 US disclosed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US disclosed
EP-1828223-A4 NOVEL BETULIN DERIVATIVES, PREPARATION THEREOF AND USE THEREOF PANACOS PHARMACEUTICALS INC (US) 2009-03-11 EP disclosed
CN-101142227-A Novel betulin derivatives, preparation thereof and use thereof PANACOS PHARMACEUTICALS INC (US) 2008-03-12 CN disclosed
EP-1828223-A2 NOVEL BETULIN DERIVATIVES, PREPARATION THEREOF AND USE THEREOF Panacos Pharmaceuticals, Inc. (US) 2007-09-05 EP disclosed
US-20060205697-A1 Novel betulin derivatives, preparation thereof and use thereof MYREXIS, INC. 2006-09-14 US disclosed
WO-2006053255-A2 NOVEL BETULIN DERIVATIVES, PREPARATION THEREOF AND USE THEREOF PANACOS PHARMACEUTICALS, INC. (US) 2006-05-18 WO disclosed
US-6861432-B2 Piperazine derivatives that destabilize androgen receptors SCHERING AKTIENGESELLSCHAFT (DE) 2005-03-01 US disclosed
CN-1021910-C LANKACIDIN DERIVATIVES AND PRODUCTION THEREOF TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1993-08-25 CN disclosed
US-4610984-A CEREBRAL INSUFFICIENCY CASSELLA AKTIENGESELLSCHAFT (DE) 1986-09-09 US disclosed
EP-0123977-A1 Substituted piperazin-1-yl-acetic-acid amides, process for their preparation and their use CASSELLA Aktiengesellschaft (DE) 1984-11-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205697-A1 Novel betulin derivatives, preparation thereof and use thereof BET1, PGGT1B, TMPO CYP1A2 279/4885SMN1; SMN2 4756/4885PKM 4329/4885
US-20090181943-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC11, HDAC3 CYP1A2 1036/4885SMN1; SMN2 3638/4885PKM 457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.